Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFN50 in Autoimmune Diseases
NCT07448298Phase 1Withdrawn
- Sponsor
- Beijing Boren Hospital
- Start
- Mar 2026
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AFN50 in systemic lupus erythematosus (SLE), Sjögren's syndrome, myasthenia gravis (MG) and 3 more, sponsored by Beijing Boren Hospital. Primary endpoint: Adverse Events at 3 months. Planned start Mar 2026; status: withdrawn.
02
Drugs
AFN50
03
Conditions
systemic lupus erythematosus (SLE)Sjögren's syndromemyasthenia gravis (MG)systemic sclerosis (SSc)idiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT07448298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07448298.